



**Damanhour University**  
**Faculty of Pharmacy**

**جامعة دمنهور**  
**كلية الصيدلة**



# **Curriculum Vitae**

**Maged Wasfy Helmy Wisa, Ph.D. Pharm D**

**Professor of**  
**Pharmacology and Toxicology**

Department of Pharmacology and Toxicology  
Faculty of Pharmacy  
Damanhour University  
Egypt

Feb 2026



**Damanshour University**  
**Faculty of Pharmacy**

جامعة دمنهور  
كلية الصيدلة



## **Maged Wasfy Helmy Wis**

**Damanshour University**  
**Faculty of Pharmacy**  
**Department of Pharmacology and Toxicology**  
**El-Gomhoriast., Damanshour, El-Bhaira, Egypt.**

**Mobile: (+2) 0122 3461 575**

**e-mail: [maged.helmy@pharm.dmu.edu.eg](mailto:maged.helmy@pharm.dmu.edu.eg)**

**[magedwhw@yahoo.com](mailto:magedwhw@yahoo.com)**

**[magedwhw88@gmail.com](mailto:magedwhw88@gmail.com)**



### **Personal information:**

**Date of birth:** August 5<sup>th</sup>, 1975

### **Current positions:**

- **Professor of Pharmacology and Toxicology, Faculty of Pharmacy, Damanshour University, Egypt.**
- **Vice-President of Damanshour National University for Academic Affairs**  
**Member of University Strategic Plan Executive Committee, Damanshour University**
- **External Auditor for National Authority for Quality Assurance and Accreditation of Education “NAQAEE”, Egypt.**
- **Member of the Advisory Committee for the Development of Higher Education of Health Science Technology, Education Development Fund of the Prime Ministry, Egypt. (Participate in designing Curriculum of Pharmacy Technology Assistant Program 2021)**
- **Professor of Pharmacology, Toxicology and Therapeutics, College of Pharmacy, Arab Academy for Science Technology & Maritime Transport (Abo Kir) (Visiting Professor)**

### **Employment History& Positions held:**

- Former **Director of International Cooperation Office, Damanshour University** from 4/11/2024 till 30/9/2025
- Former **Vice-Dean of Education and Students’ Affairs**, from 5/2/2025 till 31/7/2025



- Former **Vice-Dean of Community Services and Environment**, from 16/1/2024 till 4/2/2025
- Former **Vice Dean of Postgraduate Studies and Research**, Faculty of Pharmacy, **Damanhour** University, Egypt. from 27/7/2017 till 30/10/2022
- Former **Clinical Pharmacy Program Coordinator**, Faculty of Pharmacy, **Damanhour** University, Egypt.
- Former member of **Postgraduate Studies and Researches Committee**, Damanhour University.
- Former member of **Projects' Management Committee**, Damanhour University.
- Former **Executive Manager of Quality Assurance Unit**, Faculty of Pharmacy, **Pharos University** in Alexandria.

### **Education:**

1. **Pharm D (Professional Degree in Clinical Pharmacy)** Faculty of Pharmacy, Alexandria University, Egypt (**November 2021**).
2. **Doctor of Philosophy in Pharmaceutical sciences (Pharmacology)** Faculty of Pharmacy, Alexandria University, Egypt (**October 2009**), "Evaluation of the anti-carcinogenic actions of drugs with a possible novel target for treatment of experimentally induced breast cancer in rats"
3. **Master Degree in Pharmaceutical sciences (Pharmacology)** Faculty of Pharmacy, Alexandria University, Egypt (**January 2005**), "*The Effect of Anastrozole and / or Celecoxib on 7, 12-dimethylbenzanthracene induced rat mammary tumors*"
4. **Bachelor degree of pharmaceutical sciences**, Faculty of pharmacy, Alexandria University, Egypt (**June 1997**).

### **Employment History& Positions held:**

#### **1. Faculty of Pharmacy, Damanhour University, Egypt (9/2014 till now)**

- **Acting Vice-Dean of Education and Students' Affairs**, since 5/2/2025 till 31/7/2025
- **Acting Vice-Dean of Community Services and Environment**, since 16/1/2024 till 4/2/2025
- **Vice Dean of Postgraduate Studies and Researches**, since 17/1/2022 till 31/10/2022
- **Acting Vice Dean of Postgraduate Studies and Researches**, since 27/7/2017 till 16/1/2022
- **Professor of Pharmacology & Toxicology**, since 30/9/2020 till now.
- **Assistant Professor of Pharmacology & Toxicology**, since 30/9/2015 till 29/9/2020.
- **Lecturer of Pharmacology**, Department pharmacology& Toxicology, since 17/9/2014 till 29/9/2015.



- **Clinical Pharmacy Program Coordinator**, Faculty of Pharmacy, Damanhour University, Egypt, from 10/2014 till 30/4/2021.
- Member of **Quality Assurance Unit**, Faculty of Pharmacy, Damanhour University, Egypt, from 10/2014 till 9/2018. **Now** I am a member in the **Committee of Faculty Self-Assessment for Academic Accreditation** (Strategic Plane sector & Postgraduates Studies Sector)

## **2. Damanhour University, Egypt (9/2014 till 31/10/2022)**

- Member of **Postgraduate Studies and Researches Committee**, Damanhour University, from 8/2017 till now
- Member of **Projects' Management Committee**, Damanhour University from 19/11/2018
- Member of **International Publications and Scientific Conferences Committee**, Damanhour University

## **3. Faculty of Pharmacy & Drug Manufacturing, Pharos University in Alexandria (PUA), Egypt (2007-2014)**

- Lecturer of Pharmacology, Department pharmacology & Toxicology, from 26/10/2009 till 31/8/2014.
- Executive Manager of Quality Assurance Unit, Faculty of Pharmacy & Drug Manufacturing, PUA, from 5 / 2011 till 31/8/2014.
- Member of PUA Continuous Professional Development Team, PUA Educational Development Center, from 10 / 2012.
- Assistant Lecturer of Pharmacology, Department pharmacology & Toxicology, from 1/1/2007–25/11/ 2009

## **4. Faculty of Pharmacy, October 6 University, Egypt (2000-2006)**

- Assistant Lecturer of Pharmacology, Department pharmacology & Toxicology, from 1 / 2005 – 8 / 2006.
- Demonstrator of Pharmacology, Department pharmacology & Toxicology, from 6/ 2000 – 1 / 2005

## **Teaching Experiences:**

### **A. Damanhour University (2014-2020)**

**A.1.** Participation in teaching the following **Undergraduate students'** courses in the Department of Pharmacology and Toxicology, Faculty of Pharmacy, Damanhour University, Egypt including:

1. Pharmacology I, II (3rd year students)
2. Clinical Pharmacology (4<sup>th</sup> year students)
3. Toxicology & First Aid (4<sup>th</sup> year students)



4. Drug Interactions (5<sup>th</sup> year students)
5. Pharmacotherapeutics I, II (5<sup>th</sup> year students, Clinical Pharmacy Program)
6. Biophysics (1st year students of clinical pharmacy program 2014 - 2019)

**A.2.** Teach Pharmacology related **Postgraduate courses**, Faculty of Pharmacy, Damanhour University, Egypt including:

1. Advanced topics in Pharmacology (Master & Doctoral Degree)
2. Advanced topics in Toxicology (Master & Doctoral Degree)
3. Immunopharmacology (Master & Doctoral Degree)
4. Pharmacology of special populations
5. Cancer Biology (Master & Doctoral Degree)
6. Pharmacotherapeutics I (Clinical Pharmacy Diploma Degree)
7. Pharmacotherapeutics II (Clinical Pharmacy Diploma Degree)
8. Pharmacotherapeutics III (Clinical Pharmacy Diploma Degree)

**A.3.** Teach Pharmacology course for 1st year students of **Faculty of Nursing**, Damanhour University, Egypt as a main lecturer and Course coordinator. (**Academic year 2014-2015**)

**B. Faculty of Pharmacy and Drug Manufacturing, Pharos University in Alexandria (2007-2014)**

**B.1.** Participation in teaching the following Undergraduate students' courses in the Department of Pharmacology and Toxicology, Faculty of Pharmacy & Drug Manufacturing, Pharos University, Egypt as a lecturer (2009-2014):

1. Basic Pharmacology I (Junior students)
  2. Basic Pharmacology II (Mid-senior students)
  3. Forensic Chemistry (Mid-senior students)
  4. Pharmacotherapeutics (Senior students)
  5. Bioevaluation & Drug Screening (Senior students)
  6. Geriatric Pharmacy (Elective course for Senior & Mid-senior students)
  7. Nutrition (Elective course for Senior & Mid-senior students)
  8. Graduation Projects (Senior students)
  9. In-house part of Summer Training (Junior & Mid-senior students)
- For all of these courses, beside my participation in teaching lectures, I participate in:
- a) Designing and supervising practical parts and/or tutorials (if any)
  - b) Designing and marking of written exams & oral exams (if any)
  - c) Preparing of course specification, matrix and reports
  - d) Preparing course portfolio

**B.2.** Participation in preparing and teaching the practical sessions of the following Undergraduate students' courses in the Department of Pharmacology and Toxicology, Faculty of Pharmacy & Drug Manufacturing, Pharos University, Egypt as an assistant lecturer (2007-2009):

1. Cell Biology (Freshmen students)
2. Anatomy & Histology (Freshmen students)



3. Physiology I & II (Sophomore students)
4. Biochemistry I & II (Junior students)
5. Basic Pharmacology I (Junior students)  
Basic Pharmacology II (Mid-senior students)

**C. Faculty of Pharmacy October 6 University, Giza, Egypt (2000-2006)**

Participation in preparing and teaching the practical sessions of the following Undergraduate students' courses in the Department of Pharmacology and Toxicology, Faculty of Pharmacy, October 6 University, Egypt as a demonstrator (2000-2005) and as an assistant lecturer (2005-2006):

1. Pharmacology ( part 1, 2 and 3)
2. Clinical Pharmacology and Applied therapeutics
3. Clinical Pharmacy
4. Biological Standardization and Screening of drug
5. Toxicology and Forensic Chemistry

**Academic Experiences:**

**A. Damanhour University (2014/2015)**

**A.1.** Participate, as an **Acting Vic-Dean of Postgraduate Studies and Researches**, in the following activities:

1. Attendance of all meeting of Postgraduate Studies and Researches committee taking administrative decisions concerning the program
2. Design study plane
3. Coordination between Faculty staff members implicated in teaching of the program
4. Organization of Final Exams

**A.2.** Participate, as **Clinical Pharmacy Program Coordinator**, in the following activities:

5. Attendance of all meeting of Clinical Pharmacy Program's Higher committee & Clinical Pharmacy Program's Executive committee, taking administrative decisions concerning the program
6. Design study plane
7. Coordination between Faculty staff members implicated in teaching of the program
8. Organization of Final Exams

**A.3.** Participate, as a member of Quality Assurance Unit, in the following activities:

1. Preparation and revision of courses specifications & matrices of all courses of B.Sc. Program.



2. Participate in preparation of the project proposal of the 1<sup>st</sup> call of SDEE "Support and Development of Educational Effectiveness in Higher Education Institutions" offered by Egyptian Ministry of Higher Education
3. Acting as Deputy Executive Director of the SDEE project offered by Egyptian Ministry of Higher Education (April 2015-December 2016)
4. **Participate in Committee of Faculty Self-Assessment for Academic Accreditation** (Strategic Plane sector & Postgraduates Studies Sector)
5. **Participate as a Lecturer** in several workshops for Quality Assurance Unit in Faculty of Pharmacy:
  - a) "Understanding of Course Specification" 22/11/2014 and repeated
  - b) "Analysis of Students' Achievements Results and Writing Course Reports" 26/10/2015
  - c) "Basics of Quality Assurance in Academic Learning" 12/5/2016
  - d) "Preparation for Faculty Self-Assessment for Academic Accreditation" 21/12/2016
  - e) "Preparing of Strategic Plan of Faculty of Pharmacy, Damanhour University, Brain Storming & SWOT Analysis" 10/2/2017.

**A.3. Memberships in Faculty Committees:**

1. Member in the **Department of Pharmacology & Toxicology Council** (9/2014 till now)
2. Member in the **Quality Assurance Unit**(10/2014 till 9/2018)
3. Member of **Clinical Pharmacy Program's Higher committee** (10/2014 till now)
4. Member of **Clinical Pharmacy Program's Executive committee** (10/2014 till now)

**B. Faculty of Pharmacy and Drug Manufacturing, Pharos University in Alexandria (2007-2014)**

**B.1.** Acting as an Executive Manager of *Quality Assurance Unit*, Faculty of Pharmacy & Drug Manufacturing, Pharos University, Egypt, from 5 / 2011 till 31/8/2014. I supervise and participate in the following activities:

1. Preparation and revision of the final Self-Study proposal (2012-2013) for accreditation from National Authority for Quality Assurance and Accreditation of Higher Education (NAQAEE)
2. Design, preparation and revision of
  - a) Faculty Strategic plan (2012-2017)
  - b) Faculty Mission, Vision and Objectives, final modification (2014)
  - c) Faculty Code of ethics & Ethics of scientific research (2013)
  - d) Faculty Scientific Research Plan (2014)
  - e) B.Sc. Program Specification, Matrix and Report.



- f) Faculty Teaching & Learning Strategies
  - g) Faculty Annual Reports (2011-2014)
  - h) Cross-matching Studies of Courses, Program ILOs and National Academic Reference Standards (NAARS)
3. Organize & Participate in all activities aimed to clarify and declare all aspects and requirements of Quality Assurance between all faculty staff members, students, laboratory technicians and employees.
  4. Communicate with faculty stakeholders

**B.2.** Acting as a member of PUA Educational Development Center team, from 10 / 2012 till now, I am responsible for teaching two modules of PUA Continuous Professional Development courses including:

- a) Students' Motivation Strategies
- b) Syllabus Design

**B.3.** Memberships in Faculty Committees:

1. Member in the **Faculty Council** (6/2011 – 8/2014)
2. Member in the **Department of Pharmacology & Toxicology Council** (11/2009 - 8/2014)
3. Member in the **PUA Quality Assurance Center** (5/2011- 8/2014)
4. Member in the **Faculty Quality Assurance Unit** (5/2011- 8/2014)
5. Member in the **Faculty Strategic Plan implication committee**

### **Conferences Attended and Abstracts published:**

- *First International Pharmacy conference held by Beirut Arab University, Lebanon, under title of "Recent advances in pharmaceutical research and technology" (6,7 May 2010)*
- **Oral & Poster presentations of abstracts from Ph.D. thesis as following:**
- a) R. E. Remonda, **W. H. Maged**, A. I. ElMallah, and I. S. Saad (2010): *Antitumor Activity of Leflunomide in DMBA-induced Rat mammary Tumors. Recent advances in pharmaceutical research and technology; 1<sup>st</sup> international conference, Beirut Arab University, Lebanon (May 6-7 2010)*
  - b) S. S. Ismail, **W. H. Maged**, A. I. ElMallah, R. E. Risk, and M. Shetaa *Antitumor Activity Of Celecoxib And Leflunomide On DMBA-Induced Rat Mammary Tumors : Inhibition Of HER-2 Expression (2010): Recent advances in pharmaceutical research and technology; Beirut, Lebanon, May 6-7 2010.*
  - c) A. I. ElMallah, **W. H. Maged**, Rizk, E. Remonda. ; Ismail, S. Saad. and Ghonein, Hossam. *Growth Inhibition of DMBA-induced Rat Mammary Tumors by Rosiglitazone and Curcumin Alone or in Combination (2010): Recent advances in pharmaceutical research and technology; 1<sup>st</sup> international conference, Beirut Arab University, Lebanon (May 6-7 2010)*



- *3rd TERMS World Congress 2012 "Tissue Engineering and Regenerative Medicine Symposium". Vienna, Austria, September 5-8, 2012.*
  - **Poster Presentation under title** "*Ionically-crosslinked milk protein nanoparticles as flutamide carriers for effective anticancer activity in prostate cancer-bearing rats*".  
*Ahmed O. Elzoghby, Maged W. Helmy, Wael M. Samy, Nazik A. Elgindy.*
- *Experimental Biology 2013 Pharmacology meeting in Boston, MA, USA. April 20-24, 2013. (Poster Presentation)*
  - **3 Poster Presentations as following**
    - a) *Maged W Helmy, Hanan M El-Gowell, Rabab M Abdel-Halim and Mahmoud M El-Mas. Aggravated Nephrotoxicity Evoked By Concurrent Exposure To Cyclosporine And Indomethacin In Rats: Role Of The Endothelin ETA Receptor/TGF-beta/COX-2 Pathway. The FASEB Journal. 2013;27:654.10.*
    - b) *Hanan M El-Gowell, Maged W Helmy, Rabab M Abdel-Halim and Mahmoud M El-Mas. Celecoxib Offsets The Negative Renal Influences of Cyclosporine Via COX-2/Endothelin ETB Receptor crosstalk. The FASEB Journal. 2013;27:654.9*
    - c) *Mahmoud M El-Mas, Rabab M Abdel-Halim, Maged W Helmy and Hanan M El-Gowell. Endothelin ETA/ETB receptors modulate the hemodynamic interaction of cyclosporine with selective and nonselective nonsteroidal anti-inflammatory drugs in rats. The FASEB Journal. 2013;27:654.8*
- *6<sup>th</sup> international Conference held by Medical Research Institute, Alexandria University, 23<sup>rd</sup>-26<sup>th</sup> September 2014, under title of "Multidisciplinary Approach in Cancer Management"*
  - **Poster Presentation under title** "*Potential Growth inhibitory effects of Vitamin D on N-Methyl-N-nitrosourea/Testosterone-induced rat prostate cancer*". *Maged W. Helmy, Mona A. Salama, Mona K. Maghraby, Noha I. Saad.*
- *Experimental Biology 2015 Pharmacology meeting in Boston, MA, USA. April 2015. (Poster Presentation)*
  - *M El-Mas, M.W. Helmy, M.M. Helmy. Additive Renoprotective Effects Of Pioglitazone And Fenofibrate Against Cisplatin-Induced Renal Failure: PPARs/TNF- $\alpha$  Modulation. The FASEB Journal 29 (1 Supplement), 938.5*
- *First PUA International Conference, under title of "Advances in Pharmaceutical Sciences", Faculty of Pharmacy and Drug Manufacturing, Pharos University in Alexandria, Egypt. 27-29, October 2015. (Poster Presentation)*
  - **2 Poster Presentations as following**



- a) *ShaimaaKhamis, Maged W. Helmy, Salah Shewita, Ahmed O. Elzoghby. Novel Tumor-Targeted Protamine Nanocapsules for Combined Delivery of Letrozole and Celecoxib to Breast Cancer Bearing Mice.*
- b) *Maged W Helmy, Gamal M Omran, Sherin M Zakaria. Antitumor activity of Sulfasalazine in DMBA-induced rat mammary tumors: role of NF-κB, IGF-1 and HER-2 axis inhibition.*
- **4th World Congress on Breast Pathology and Cancer Diagnosis (Breast Pathology-2017)**, held during August 23-24, 2017 at Toronto, Canada.
- **Poster Presentation under title "Reversal of TAM Resistance by Calcitriol and Tretinoin Combined Therapy Is Mediated Mainly by Induction of Survivin"**. *Helmy MW, Sakr S, Matta CA, Ahmad MA, El-Abd E.*
- **4<sup>th</sup> Future University International Conference of Pharmaceutical Sciences**, held on January 31-February 2, 2017, in Cairo, Egypt.
- **Poster Presentation under title "Evaluation of the potential antitumor effects of Sulfasalazine alone or in combination with Sorafenib on hepatocellular Carcinome cell line"** *MariumShamaa, Maged W. Helmy, HosnyFouad, MedhatHaroun, NerminMoussa.*
- **Experimental Biology 2017 Pharmacology meeting in CHICAGO, USA. April 22-26, 2017.** (Poster Presentation)
- *Maged W. Helmy, Mai M. Helmy and Mahmoud M. El-Mas. Enhanced Lipoxigenase/LTD4 Activity Accounts For The Exaggerated Hypertensive And Nephrotoxic Effects Of Cyclosporine Plus Indomethacin In Rats. The FASEB Journal 31 (1 Supplement) Abstract Number: lb541*
- **Experimental Biology 2018 Pharmacology meeting in San Diego, California, USA. April 21-25, 2018.** (Poster Presentation)
- *Mai M. Helmy, Maged W. Helmy, and Mahmoud M. El-Mas. Upregulation of cystathionine-γ-lyase/hydrogen sulfide pathway underlies the celecoxib counteraction of the cyclosporine-induced hypertension and renal insult in rats. The FASEB Journal 32 (1 Supplement) Abstract Number: 562.9*
- **BioVision 2018 Alexandria, Egypt. April 2018.** (Poster Presentation)
- *Abdel Halim M. Elkishky, NerminMoussa, Maged W. Helmy, MedhatHaroun. "In-Vitro Evaluation of the Potential Antitumor Effect of GANT61 and BI-847325 in the Treatment of Lung Cancer"*
- *Mohammed Youssef, NerminMoussa, Maged W. Helmy, MedhatHaroun "Evaluation of The Potential Antitumor Effects of Gant61 and/or Dactolisib On Prostate Cancer Cells"*



- **1<sup>st</sup> International Pharmaceutical Sciences Conference on 11, 12 August 2018, in Menoufia University, Egypt. (Attendance)**
- **1<sup>st</sup> International Conference on Pharmaceutical & Healthcare Sciences on 6, 7 November 2019, in Faculty of Pharmacy, Alexandria University, Egypt. (2 Poster Presentation)**
  - **Maged. W. Helmy, Asser I. Ghoneim, Mohamed A. Katary, Rana K. Elmahdy. *The synergistic anti-proliferative effect of the combination of diosmin and BEZ-235 (dactolisib) on the HCT-116 colorectal cancer cell line occurs through inhibition of the PI3K/Akt/mTOR/NF-κB axis.***
  - **Doaa M. El-Tedawy, Mohammad M Abd-Alhaseeb, Maged W. Helmy, Asser I. Ghoneim. *Anti-arthritic activity of systemic bee venom through multiple mechanisms.***
- **3<sup>rd</sup> International Conference on Innovation in Pharmaceutical Sciences on 14 May 2022, in Faculty of Pharmacy, Pharos University in Alexandria, Egypt. (Chairperson and 1 Poster)**
- **1<sup>st</sup> International Conference on Applied Pharmaceutical Research Serving Human Health 20 & 21 September 2022, in Faculty of Pharmacy, Damanhour University, Egypt. (Conference Secretary General and 3 Posters)**
- **2<sup>nd</sup> International Conference on Pharmaceutical & Healthcare Sciences on 23 & 24 November 2022, in Faculty of Pharmacy, Alexandria University, Egypt. (3 Poster Presentations)**
- **7<sup>th</sup> international Conference held by Medical Research Institute, Alexandria University, 13<sup>v</sup>& 24 May 2023, under title of "Milestone in Cancer Research from Genomics to Practice" (2 Posters)**
- **Experimental Biology 2023, ASPET 2023, May 18 - 21, 2023 at St. Louis Union Station, St Louis, Missouri, USA. (Poster Presentation)**
  - **El-Mas M, Kassem AB, El-Bassiouny NA, Helmy MW, El-Kerm Y, Serageldin MA. *Metformin alleviates chemotherapy-induced toxicities in non-diabetic breast cancer patients: a randomized controlled study. J Pharmacol Exp Ther June 2023, 385 (S3) 247; DOI: <https://doi.org/10.1124/jpet.122.159900>".***
- **19<sup>th</sup> Medical Research Institute Conference & 7<sup>th</sup> International conference of Medical Research Institute, 13 & 14 May 2023.**
  - **Oral Presentation:**



- *Insulin Like Growth Factor Pathway as A Potential Target to Overcome Tamoxifen Resistance*
- *Exploring the Potential of Antitumor Effects of Dasatinib Alone or in Combination with Celecoxib in Colorectal Carcinoma Cell Line.*
- ***American Society of Pharmacology and Experimental Therapeutics 2023 Annual Meeting, May 18-21 St. Louis Union Station, MO, USA.***
  - *Poster Presentation:*
  - *Metformin Alleviates Chemotherapy-Induced Toxicities in Non-Diabetic Breast Cancer Patients: A Randomized Controlled Study. Mahmoud El-Mas,1 Amira B. Kassem,2 Noha A. El-Bassiouny,2 Maged W. Helmy,3 Yasser El-Kerm,4 and Manar A. Serageldin5*

### **Workshops Attended**

1. Workshops of "**Basic Concepts & Requirements of Quality Assurance and Accreditation of Higher Education**" held in 5,6 June 2008 by National Authority for Quality Assurance and Accreditation of Higher Education (NAQAEE)
2. Workshop of "**Basic Techniques in Cell Culture**" held in November 2009 by Medical Technology Center for Research, Medical Research Institute, Alexandria University, Egypt
3. Workshops of "**Institutional Self Assessment of Higher Education Institutes**" held in 13-17 December 2009 by National Authority for Quality Assurance and Accreditation of Higher Education (NAQAEE)
4. Workshops of "**External Auditing of Higher Education Institutes**" held in 27-31 December 2009 by National Authority for Quality Assurance and Accreditation of Higher Education (NAQAEE)
5. Continuing Professional Development (CPD) Program in teaching and learning delivered by the Institute of International Education to PUA staff members, 29 & 31 March 2012, at Pharos University in Alexandria.
6. "Basics of Bioinformatics" workshop held by Pharos University in Alexandria, 22 & 23 April, 2012.
7. Workshop of "**Culture and Leadership**" held as a Continuous Professional Development (CPD) Program, delivered by the Institute of International Education to PUA staff members. **5 January 2014, at Pharos University in Alexandria.**
8. Training Course on "**Effective Presentation Skills**", organized by Faculty and leadership Development Center, Alexandria University, 8-9 March 2014.
9. Training Course on "**The Credit Hour System**", organized by Faculty and leadership Development Center, Alexandria University, 15-16 March 2014.



10. Workshop of "**Gene expression analysis on large scale using Microarray and Real-Time PCR techniques**" held in Molecular Biology Lab, Cairo University Research Park, 8<sup>th</sup>-11<sup>th</sup> September, 2014.
11. Workshop of "**Pharmaceutical Vigilance**" held in Damanhour, Elbahira, Egypt, February 23<sup>rd</sup> 2015 under supervision under supervision of Egyptian Pharmaceutical Vigilance Center.
12. Workshop of "**Application of Pharmacy NARS: from Content to Competency-based Curricula**" held by National Authority for Quality Assurance and Accreditation of Higher Education (NAQAA) and Agence Universitaire de la Francophonie (AUF) on 18<sup>th</sup> & 19<sup>th</sup> December 2017, Cairo, Egypt.
13. Workshop of "**The Future of Biotechnology in Egypt**" held in Damanhour, Elbahira, Egypt, 5<sup>th</sup> February 2018 under supervision of Damanhour University.
14. Workshop of "**Developing Institutional Internationalization**" held by National Erasmus+ office on 14<sup>th</sup> & 15<sup>th</sup> May 2018, Alexandria, Egypt.
15. Workshop of "**Blended E-Learning Skills**" held in Damanhour, Elbahira, Egypt, August 6-7 2018 under supervision of E- Learning & Management Center, Damanhour University.
16. Workshop of "**Isolation of Mesenchymal Stem Cells from Rats**" held in CERRMA unit, Faculty of Medicine, Alexandria University, Egypt, July 16-17 2019
17. Workshop of "**Research Methods**" held in FLDC unit, Damanhour University, Egypt, August 19-20, 2019.
18. Workshop of "**University Management**" held in FLDC unit, Damanhour University, Egypt, August 21-22, 2019.
19. Workshop of "**Innovative Problem-solving and Decision-making**" held in FLDC unit, Alexandria University, Egypt, April 25-26, 2020.
20. Workshop of "**E-Exam**" held in FLDC unit, Alexandria University, Egypt, April 29-30, 2020.

### **Research Projects membership**

1. **Project ID: 5731, Code: TC/3/April/2013/DNPI5731 (Targeted Call; Towards Development of National Pharmaceuticals Industries), "Inhalable Anticancer Drug-loaded Nanocomposites for Enhanced Lung Cancer Targeting"**; Science & Technology Development Fund (STDF), Ministry of Scientific Research, Egypt. Role in the project: **CO-PI.**
2. **Project ID: 15053 (Innovation Grant), "Synthesis and evaluation of drug-polymer conjugate nanomicelles as emerging platform for targeted brain tumor therapy"**; Science & Technology Development Fund (STDF), Ministry of Scientific Research, Egypt. Role in the project: **Partner.**
3. **Project ID: 25717 (Young Researcher – Call 7), "Design and Synthesis of novel selective Estrogen Receptor modulators"**; Science & Technology Development Fund (STDF), Ministry of Scientific Research, Egypt. Role in the project: **CO-PI.**



## Patent Registration:

1. **Patent Application No.: 554/2017- Ministry of Scientific Researches, Academy of Scientific Research and Technology (Alexandria Office)**

**Title:** Multi-compartmental nano-structural vehicle for co-delivery of resveratrol, monascin and ankaflavin for breast cancer treatment

**Inventors:** Shaymaa W El-Far, Helmy Wasfy Helmy, Sherine N Khattab, Adnan A Bekhit, Ahmed A Hussein, Ahmed O. Elzoghby.

2. **Patent Application No.: 1579/2017- Ministry of Scientific Researches, Academy of Scientific Research and Technology (Alexandria Office)**

**Title:** Mannosylated albumin-quantum dot nano-theranostics for breast cancer

**Inventors:** Dina G. Zayed, Shaker M. Ebrahim, Helmy Wasfy Helmy, Sherine N. Khattab, Kadria A. Elkhodairy and Ahmed O. Elzoghby.

3. **Patent Application No.: 1581/2017- Ministry of Scientific Researches, Academy of Scientific Research and Technology (Alexandria Office)**

**Title:** Amphiphilic zein-lactoferrin nanomicelles for targeted drug delivery to breast cancer

**Inventors:** Sally A. Sabraa, Ahmed O. Elzoghby, Salah A. Sheweita, Medhat Haroun, Maged W. Helmy.

4. **Patent Application No.: 420/2018- Ministry of Scientific Researches, Academy of Scientific Research and Technology (Alexandria Office)**

**Title:** Amphiphilic maltodextrin-based polymeric micelles for tumor-targeted drug delivery

**Inventors:** Anwar DM, Khattab SN, Helmy Wasfy Helmy, Kamal MK, Bekhit AA, Elkhodairy KA, Elzoghby AO.

5. **Patent Application No.: 957/2018 - Ministry of Scientific Researches, Academy of Scientific Research and Technology (Main Office, Cairo, Egypt). Presented by STDF via Project ID: 5731, Code: TC/3/April/2013/DNPI5731**

**Title:** Inhalable lactoferrin-chondroitin dual-targeted cubosomal nanocomposites for enhanced lung cancer targeting

**Inventors:** STDF co-Inventors: Ahmed Elzoghby, Hadeer Mamdouh, Helmy Wasfy Helmy, Magda Samaha

6. **Patent Application No.: 1119/2018- Ministry of Scientific Researches, Academy of Scientific Research and Technology (Main Office, Cairo, Egypt). Presented by STDF via Project ID: 5731, Code: TC/3/April/2013/DNPI5731**

**Title:** Inhalable hyaluronate/lactoferrin-decorated lipid nanocomposites for localized drug delivery to lung cancer

**Inventors:** STDF co-Inventors: Ahmed Elzoghby, Dalia Kabary, Helmy Wasfy Helmy, Kadria Elkhodairy

7. **Patent Application No.: 1501/2018- Ministry of Scientific Researches, Academy of Scientific Research and Technology (Main Office, Cairo, Egypt). Presented by STDF via Project ID: 5731, Code: TC/3/April/2013/DNPI5731**

**Title:** Inhalable dual-targeted protein-lipid nanocomposites for enhanced lung cancer targeting



**Inventors:**STDF co-Inventors: Ahmed Elzoghby, Nayera Kamel, Helmy Wasfy Helmy, Magda Samaha

8. **Patent Application No.: 1479/2019- Ministry of Scientific Researches, Academy of Scientific Research and Technology (Main Office, Cairo, Egypt). Presented by STDF via Project ID: 5731, Code: TC/3/April/2013/DNPI5731**

**Title:**Amphiphilic zein-chondroitin magnetic nanomicelles as cancer theranostics

**Inventors:**STDF co-Inventors: Ahmed Elzoghby, Kholod Elhasani, Helmy Wasfy Helmy, Adnan Bekhit, Sherine Khattab.

9. **Patent Application No.: 1610/2019- Ministry of Scientific Researches, Academy of Scientific Research and Technology (Main Office, Cairo, Egypt). Presented by STDF via Project ID: 5731, Code: TC/3/April/2013/DNPI5731**

**Title:**Lactoferrin-mesoporous silica nanohybrids for tumor-targeted chemo-herbal drug delivery

**Inventors:**STDF co-Inventors: Ahmed Elzoghby, Omnia Ali, Helmy Wasfy Helmy, Adnan Bekhit, Sherine Khattab.

10. **Patent Application No.: 536/2020- Ministry of Scientific Researches, Academy of Scientific Research and Technology (Alexandria Office)**

**Title:**Nanoparticles Loaded with food-based bioactive compounds in treatment of Infected lung cancer

**Inventors:**Marian Gerges Wahieb, Sana H. Omar, Rowida Kalil Salah Eldin, Heba Khairy Hassen, Ahmed O. Elzoghby Helmy Wasfy Helmy.

### **Membership of Professional Societies:**

1. Egyptian Pharmacist Syndicate (EPS) – ID:37924
2. Member of Egyptian Society of Natural Toxins (ESNT), membership No.: 947

### **Number of Publications in International peer-reviewed research Journal:**

106 Publications in Scopus & 102 Publications in Google Scholar (last update 1/2/20226)

### **Publications Impact:**

Citation Metrics	Bibliographic database	
	Scopus	Google Scholar
Citations	3414	3947
<b>h-index</b>	<b>37</b>	<b>39</b>

**Web of Science Researcher ID** [AFU-2420-2022](#)

<https://www.webofscience.com/wos/author/record/AFU-2420-2022>

**Scopus ID** 55615138600

<https://www.scopus.com/authid/detail.uri?authorId=55615138600>



ORCID No. 0000-0003-0375-6762

<https://orcid.org/0000-0003-0375-6762>

Google Scholar Link

[https://scholar.google.com/citations?hl=en&user=Igo8qaUAAAAJ&view\\_op=list\\_works&sortby=pubdate](https://scholar.google.com/citations?hl=en&user=Igo8qaUAAAAJ&view_op=list_works&sortby=pubdate)

### **Publications:**

1. **Helmy M.W.**, Sharabi F.M., Rizk R.E., and Ismail S.S. (2005): *Comparative effects of tamoxifen versus anastrozole in an experimental mammary carcinogenesis model*. JMRI., 26: 1-6.
2. Ahmed O. Elzoghby, **Maged W. Helmy**, Wael M. Samy, Nazik A. Elgindy. *Novel ionically crosslinked casein nanoparticles for flutamide delivery: formulation, characterization, and in vivo pharmacokinetics*. *International Journal of Nanomedicine*. 2013;8 1721–1732
3. Ahmed O. Elzoghby, **Maged W. Helmy**, Wael M. Samy, Nazik A. Elgindy. *Spray-dried casein-based micelles as a vehicle for solubilization and controlled delivery of flutamide: Formulation, characterization, and in vivo pharmacokinetics* *Eur. J. Pharm. Biopharm.* 2013 Aug;84(3):487-96
4. Ahmed O. Elzoghby, **Maged W. Helmy**, Wael M. Samy, Nazik A. Elgindy. *Micellar delivery of flutamide via milk protein nanovehicles enhances its anti-tumor efficacy in androgen-dependent prostate cancer rat model*. *Pharm. Res.* 2013 Oct;30(10):2654-63
5. Ahmed O. Elzoghby, Noha I. Saad, **Maged W. Helmy**, Wael M. Samy, Nazik A. Elgindy. *Ionically crosslinked milk protein nanoparticles as flutamide carriers for effective anticancer activity in prostate cancer-bearing rats*. *Eur J Pharm Biopharm.* 2013 Aug;85(3):444-51
6. Hanan M. El-Gowell, **Maged W. Helmy**, Rabab M. Ali, Mahmoud M. El-Mas. *Celecoxib offsets the negative renal influences of cyclosporine via modulation of the TGF- $\beta$ 1/IL-2/COX-2/endothelin ETB receptor cascade*. *Toxicology and Applied Pharmacology*. 2014. *Toxicology and Applied Pharmacology* 275 (2014) 88–95
7. Mai M. Helmy, **Maged W. Helmy**, Dina M. Abd Allah, Ahmad M. Abo Zaid, Mahmoud M. Mohy El-Din Mohy El-Din. *Selective ETA receptor blockade protects against cisplatin-induced acute renal failure in male rats*. *European Journal of Pharmacology* 730 (2014) 133–139
8. **Maged W. Helmy**, Mai M. Helmy, Dina M. Abd Allah, Ahmad M. Abo Zaid, Mahmoud M. Mohy El-Din Mohy El-Din. *Role of nitrenergic and endothelin pathways modulations in cisplatin-induced nephrotoxicity in male rats*. *JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY* 2014, 65, 3, 393-399
9. Mahmoud M El-Mas, **Maged W Helmy**, Rabab M Abdel-Halim, and Hanan M El-Gowell. *Celecoxib, but not indomethacin, ameliorates the hypertensive and perivascular fibrotic actions of cyclosporine in rats: Role of endothelin signaling*. *Toxicology and Applied Pharmacology* 284 (2015) 1–7.



10. [Maged W. Helmy](#), Hanan M. El-Gowell, Rabab M. Ali, Mahmoud M. El-Mas. **Endothelin ETA receptor/lipid peroxides/COX-2/TGF- $\beta$ 1 signaling underlies aggravated nephrotoxicity caused by cyclosporine plus indomethacin in rats.** *British Journal Of Pharmacology* 05/2015; DOI: 10.1111/bph.13199
11. MM Helmy, [MW Helmy](#), MM El-Mas. **Additive Renoprotection by Pioglitazone and Fenofibrate against Inflammatory, Oxidative and Apoptotic Manifestations of Cisplatin Nephrotoxicity: Modulation by PPARs.** *PloS one*, 2015; 10 (11), e014230.
12. AS Hanafy, RM Farid, [MW Helmy](#), SS ElGamal. **Pharmacological, toxicological and neuronal localization assessment of galantamine/chitosan complex nanoparticles in rats: future potential contribution in Alzheimer's disease management.** *Drug delivery*, 2016
13. Elzoghby AO, Mostafa SK, [Helmy MW](#), El-Demellawy M, Shewita S, **Superiority of aromatase inhibitor and cyclooxygenase-2 inhibitor combined delivery: Hyaluronate-targeted versus PEGylated protamine nanocapsules for breast cancer therapy,** *Int J Pharm* 529 (2017) 178-192.
14. Elzoghby AO, Mostafa SK, [Helmy MW](#), El-Demellawy M, Shewita S. **Multi-Reservoir Phospholipid Shell Encapsulating Protamine Nanocapsules for Co-Delivery of Letrozole and Celecoxib In Breast Cancer Therapy.** *Pharm Res* 34 (2017) 1956–1969.
15. Ahmed O Elzoghby, Sarah A El-Lakany, [Maged W Helmy](#), Marwa M Abu-Serie, Nazik A Elgindy. **Shell-crosslinked zein nanocapsules for oral codelivery of exemestane and resveratrol in breast cancer therapy.** *Nanomedicine* 12 (24) (2017), 2785-2805
16. Shaymaa W El-Far, [Maged W Helmy](#), Sherine N Khattab, Adnan A Bekhit, Ahmed A Hussein, Ahmed O Elzoghby. **Phytosomal bilayer-enveloped casein micelles for codelivery of monascus yellow pigments and resveratrol to breast cancer.** *Nanomedicine* 13 (5) (2018), 481-499
17. [Maged W Helmy](#), Mai M Helmy, Mahmoud M El-Mas. **Enhanced lipoxigenase/LTD4 activity accounts for the exaggerated hypertensive and nephrotoxic effects of cyclosporine plus indomethacin in rats.** *Biomedicine & Pharmacotherapy* (2018) 102, 309-316
18. Dalia M Kabary, [Maged W Helmy](#), Kadria A Elkhodairy, Jia-You Fang, Ahmed O Elzoghby. **Hyaluronate/lactoferrin layer-by-layer-coated lipid nanocarriers for targeted co-delivery of rapamycin and berberine to lung carcinoma.** *Colloids and Surfaces B: Biointerfaces* (2018) 169, 183-194
19. Sally A Sabra, Ahmed O Elzoghby, Salah A Sheweita, Medhat Haroun, [Maged W Helmy](#), Maha A Eldemellawy, Ying Xia, David Goodale, Alison L Allan, Sohrab Rohani. **Self-assembled amphiphilic zein-lactoferrin micelles for tumor targeted co-delivery of rapamycin and wogonin to breast cancer.** *European Journal of Pharmaceutics and Biopharmaceutics* (2018) 128, 156-169
20. Mayada M Elgohary, [Maged W Helmy](#), Elsayeda-Zeinab Abdelfattah, Doaa M Ragab, Sana M Mortada, Jia-You Fang, Ahmed O Elzoghby. **Targeting sialic acid residues on lung cancer cells by inhalable boronic acid-decorated albumin nanocomposites for combined chemo/herbal therapy.** *Journal of Controlled Release* (2018) 285, 230-243
21. Rabab M Ali, Muhammad Y Al-Shorbagy, [Maged W Helmy](#), Hanan S El-Abhar. **Role of Wnt4/ $\beta$ -catenin, Ang II/tgfb, Ace2, Nf- $\kappa$ b, and Il-18 in attenuating renal ischemia/reperfusion-induced injury in rats treated with Vit D and pioglitazone.** *European journal of pharmacology* (2018) 831, 68-76



22. Tarek K Motawi, Hebatallah A Darwish, ImanDiab, [Maged W Helmy](#), Mohamed H Noureldin. **Combinatorial strategy of epigenetic and hormonal therapies: A novel promising approach for treating advanced prostate cancer.** Life sciences (2018) 198, 71-78
23. [Maged W. Helmy](#), Mai M. Helmy, Mahmoud M. El-Mas. **Enhanced lipoxigenase/LTD4 signaling accounts for the exaggerated hypertensive and nephrotoxic effects of cyclosporine plus indomethacin in rats.** Biomedicine & Pharmacotherapy 102 (2018) 309–316.
24. Shaymaa W El-Far, [Maged W Helmy](#), Sherine N Khattab, Adnan A Bekhit1, Ahmed A Hussein & Ahmed O Elzoghby. **Folate conjugated vs PEGylated phytosomal casein nanocarriers for codelivery of fungaland herbal-derived anticancer drugs.** Nanomedicine (Lond.) (2018) 13(12), 1463–1480
25. Rabab M. Alia, Muhammad Y. Al-Shorbagy, [Maged W. Helmy](#), Hanan S. El-Abhar. **Role of Wnt4/ $\beta$ -catenin, Ang II/TGF $\beta$ , ACE2, NF- $\kappa$ B, and IL-18 in attenuating renal ischemia/reperfusion-induced injury in rats treated with Vit D and pioglitazone.** European Journal of Pharmacology 831 (2018) 68–76
26. Sally A. Sabraa, Ahmed O. Elzoghby, Salah A. Sheweita, Medhat Haroun, [Maged W. Helmy](#), Maha A. Eldemellawy, Ying Xiag, David Goodale, Alison L. Allang, Sohrab Rohani. **Self-assembled amphiphilic zein-lactoferrin micelles for tumor targeted codelivery of rapamycin and wogonin to breast cancer.** European Journal of Pharmaceutics and Biopharmaceutics 128 (2018) 156–169
27. Ahmed S AbdElhamid, [Maged W Helmy](#), Shaker M Ebrahim, Mohammed Bahey-El-Din, Dina G Zayed, Esmat A Zein El Dein, Sanaa A El-Gizawy & Ahmed O Elzoghby. **Layer-by-layer gelatin/chondroitin quantum dots-based nanotheranostics: combined rapamycin/celecoxib delivery and cancer imaging.** Nanomedicine (Lond). 2018 Aug 3. doi: 10.2217/nnm-2018-0028.
28. Dalia M. Kabary, [Maged W. Helmy](#), Kadria A. Elkhodairy, Jia-You Fange, Ahmed O. Elzoghby. **Hyaluronate/lactoferrin layer-by-layer-coated lipid nanocarriers for targeted codelivery of rapamycin and berberine to lung carcinoma.** Colloids and Surfaces B: Biointerfaces 169 (2018) 183–194
29. Mahmoud M AbdElwakil, Moustafa T Mabrouk, [Maged W Helmy](#), Elsayeda-Zeinab A Abdelfattah, Sachin K Khiste, Kadria A Elkhodairy & Ahmed O Elzoghby. **Inhalable lactoferrin–chondroitin nanocomposites for combined delivery of doxorubicin and ellagic acid to lung carcinoma.** Nanomedicine (Lond). 2018 Aug; 13(16):2015-2035.
30. Dalia M. Kabary, [Maged W. Helmy](#), Elsayeda-Zeinab A. Abdelfattah, Jia-You Fang, Kadria A. Elkhodairy, Ahmed O. Elzoghby, **Inhalable multi-compartmental phospholipid enveloped lipid core nanocomposites for localized mTOR inhibitor/herbal combined therapy of lung carcinoma.** European Journal of Pharmaceutics and Biopharmaceutics 130 (2018) 152–164
31. Mayada M. Elgohary, [Maged W. Helmy](#), Elsayeda-Zeinab A. Abdelfattah, Doaa M. Ragabb, Sana M. Mortada, Jia-You Fange, Ahmed O. Elzoghby. **Targeting sialic acid residues on lung cancer cells by inhalable boronic acid decorated albumin nanocomposites for combined chemo/herbal therapy.** Journal of Controlled Release 285 (2018) 230–243
32. Mayada M Elgohary, [Maged W Helmy](#), Sana M Mortada & Ahmed O Elzoghby. **Dual-Targeted Nano-in-Nano Albumin Carriers Enhance The Efficacy of Combined Chemo/Herbal Therapy of Lung Cancer.** Nanomedicine (Lond). 2018 Sep; 13(17):2221-2224. doi: 10.2217/nnm-2018-0097.



33. Ahmed S Abdelhamid, Dina G Zayed, [Maged W Helmy](#), Shaker M Ebrahim, Mohammed Bahey-El-Din, Esmat A Zein-El-Dein, Sanaa A El-Gizawy & Ahmed O Elzoghby. **Lactoferrin-tagged quantum dots-based theranostic nanocapsules for combined COX-2 inhibitor/herbal therapy of breast Cancer.** *Nanomedicine (Lond)*. 2018 Oct 19. doi: 10.2217/nmm-2018-0196
34. Anwar DM, Khattab SN, [Helmy MW](#), Kamal MK, Bekhit AA, Elkhodairy KA, Elzoghby AO. **Lactobionic/Folate Dual-Targeted Amphiphilic Maltodextrin-Based Micelles for Targeted Codelivery of Sulfasalazine and Resveratrol to Hepatocellular Carcinoma.** *Bioconjug Chem*. 2018 Sep 19;29(9):3026-3041.
35. Sarah A. El-Lakany, Nazik A. Elgindy, [Maged W. Helmy](#), Marwa M Abu-Serie & Ahmed O. Elzoghby. **Lactoferrin-decorated vs. PEGylated zein nanospheres for combined aromatase inhibitor and herbal therapy of breast cancer.** *Expert Opin Drug Deliv*. 2018 Sep; 15(9):835-850.
36. Mona A. Abdelmoneem, Mazen Mahmoud, Amira Zaky, [Maged W. Helmy](#), Marwa Sallam, Jia-You Fang, Kadria A. Elkhodairy, Ahmed O. Elzoghby. **Dual-targeted casein micelles as green nanomedicine for synergistic phytotherapy of hepatocellular carcinoma.** *Journal of Controlled Release* 287 (2018) 78–93
37. Fatma M. Abdallah, [Maged W. Helmy](#), Mohamed A. Katary, Asser I. Ghoneim. **Synergistic antiproliferative effects of curcumin and celecoxib in hepatocellular carcinoma HepG2 cells.** *Naunyn-Schmiedeberg's Arch Pharmacol*. 2018 Dec; 391(12):1399-1410.
38. Sherin Zakariaa, [Maged Wasfy Helmy](#), Ahmed Salahuddin, Gamal Omran. **Chemopreventive and antitumor effects of benzyl isothiocyanate on HCC models: A possible role of HGF /pAkt/ STAT3 axis and VEGF.** *Biomedicine & Pharmacotherapy* 108 (2018) 65–75
39. Ibrahim El Sayed, [Maged W. Helmy](#), Hanan S. El-Abhar. **Inhibition of SRC/FAK cue: A novel pathway for the synergistic effect of rosuvastatin on the anti-cancer effect of dasatinib in hepatocellular carcinoma.** *Life Sciences* 213 (2018) 248–257
40. Hadeer M Abdelaziz, Ahmed O Elzoghby, [Maged W Helmy](#), Magda W Samaha, Jia-You Fang, May S. Freag. **Liquid crystalline assembly for potential combinatorial chemo-herbal drug delivery to lung cancer cells.** *International Journal of Nanomedicine* 2019;14 499–517
41. Mai M. Helmy, [Maged W. Helmy](#), Mahmoud M. El-Ma. **Upregulation of cystathionine- $\gamma$ -lyase/hydrogen sulfide pathway underlies the celecoxib counteraction of cyclosporine-induced hypertension and renal insult in rats.** *Prostaglandins and Other Lipid Mediators* 141 (2019) 1–10
42. Dina G. Zayed, Shaker M. Ebrahim, Maged W. Helmy, Sherine N. Khattab, Mohammed Bahey-El-Din, Jia-You Fang, Kadria A. Elkhodairy and Ahmed O. Elzoghby. **Combining hydrophilic chemotherapy and hydrophobic phytotherapy via tumor-targeted albumin-QDs nano-hybrids: covalent coupling and phospholipid complexation approaches.** *Journal of Nanobiotechnology*, 2019 Jan 19;17(1):7. doi: 10.1186/s12951-019-0445-7.
43. Nayra M Kamel, [Maged W Helmy](#), Elsayeda-Zeinab Abdelfattah, Sherine Nabil Khattab, Doaa Ragab, Magda W Samaha, Jia-You Fang, Ahmed O Elzoghby. **Inhalable dual-targeted hybrid lipid nanocore-protein shell composites for combined delivery of genistein and all-trans retinoic acid to lung cancer cells.** *ACS Biomaterials Science & Engineering Publication* date 2019/3/6



44. Lobna M Abdel Moneim, [Maged W Helmy](#), Hanan S El-Abhar. **Co-targeting of endothelin-A and vitamin D receptors: a novel strategy to ameliorate cisplatin-induced nephrotoxicity.** *Pharmacological Reports*. 2019 Apr 25;71(5):917-925. doi: 10.1016/j.pharep.2019.04.018.
45. Mariam Zewail, Noha Nafee, Maged W. Helmy, Nabila Boraie. **Coated nanostructured lipid carriers targeting the joints-An effective and safe approach for the oral management of rheumatoid arthritis.** *International Journal of Pharmaceutics* 567 (2019) 118447
46. Nayra M Kamel, Maged W Helmy, Magda W Samaha, Doaa Ragab & Ahmed O. Elzoghby. **Multicompartmental lipid-protein nanohybrids for combined tretinoin/herballung cancer therapy.** *Nanomedicine (Lond)*. 2019 doi: [doi.org/10.2217/nnm-2019-0090](https://doi.org/10.2217/nnm-2019-0090)
47. Mona A. Abdelmoneem, Manar A. Elnaggar, Ruwan S. Hammady, Shaza M. Kamel, Maged W. Helmy, Mohammad A. Abdulkader, Amira Zaky, Jia-You Fang, Kadria A. Elkhodairy, and Ahmed O. Elzoghby. **Dual-Targeted Lactoferrin Shell-Oily Core Nanocapsules for Synergistic Targeted/Herbal Therapy of Hepatocellular Carcinoma.** *ACS Appl. Mater. Interfaces* 2019, 11, 26731–26744
48. Basma M. Abdelaziz, Maged W. Helmy, Mohamed A. Katary, Mohammad M. Abd-Alhaseeb, Asser I. Ghoneim. **Protective effects of Astragalus kahiricus root extract on ethanol-induced retrograde memory impairments in mice.** *J Herbmed Pharmacol*. 2019; [8\(4\)](#): 295-301. doi: [10.15171/jhp.2019.43](https://doi.org/10.15171/jhp.2019.43)
49. [Helmy MW](#), Ghoneim AI, Katary MA, Elmahdy RK. **The synergistic anti-proliferative effect of the combination of diosmin and BEZ-235 (dactolisib) on the HCT-116 colorectal cancer cell line occurs through inhibition of the PI3K/Akt/mTOR/NF- $\kappa$ B axis.** *Molecular Biology Report*. 2020 Mar;47(3):2217-2230. doi: 10.1007/s11033-020-05327-4
50. Omnia M. Ali, Adnan A. Bekhit, Sherine N. Khattab, [Maged W. Helmy](#), Yasser S. Abdel-Ghany, Mohamed Teleb, Ahmed O. Elzoghby. **Synthesis of lactoferrin mesoporous silica nanoparticles for pemetrexed/ellagic acid synergistic breast cancer therapy.** *Colloids and Surfaces B: Biointerfaces*. Volume 188, April 2020, 110824
51. Hadeer M. Abdelaziz, Ahmed O. Elzoghby, [Maged W. Helmy](#), Elsayeda-Zeinab A. Abdelfattah, Jia-You Fang, Magda W. Samaha, and May S. Freag. **Inhalable Lactoferrin/Chondroitin-Functionalized Monoolein Nanocomposites for Localized Lung Cancer Targeting.** *ACS Biomaterials Science & Engineering* 2020 6 (2), 1030-1042. DOI: 10.1021/acsbomaterials.9b01639
52. Ragwa M Farid, Passent M E Gaafar, Heba A Hazzah, [Maged W Helmy](#) & Ossama Y Abdallah. **Chemotherapeutic potential of L-carnosine from stimuli-responsive magnetic nanoparticles against breast cancer model.** *Nanomedicine (Lond)*. 2020 Apr 2. doi: 10.2217/nnm-2019-0428.
53. Noha Nafee, Dina M. Gaber, Ahmed O. Elzoghby, [Maged W. Helmy](#) & Osama Y. Abdallah. **Promoted Antitumor Activity of Myricetin against Lung Carcinoma Via Nanoencapsulated Phospholipid Complex in Respirable Microparticles.** *Pharm Res* 37, 82 (2020). <https://doi.org/10.1007/s11095-020-02794-z>
54. Mohamed Gaber; Kholod A. Elhasany; Saly Sabra; [Maged W. Helmy](#); Jia-You Fang; Sherine N. Khattab; Adnan A. Bekhit; Mohamed Teleb; Kadria A. Elkodairy; Ahmed O. Elzoghby. **Co-Administration of Tretinoin Enhances the Anti-Cancer Efficacy of Etoposide via Tumor-**



*Targeted Green Nano-Micelles. Colloids and Surfaces B: Biointerfaces* 2020-04-25 ,  
DOI: 10.1016/j.colsurfb.2020.110997

55. Jilan A. Nazeam, Walaa A. AL-Shareef, [Maged W. Helmy](#), Alaadin E. El-Haddad. **Bioassay-guided isolation of potential bioactive constituents from pomegranate agrifood by-product** .Food Chemistry 326 (2020) 126993
56. Perihan A.Elzahhar, Shrouk M.Abd El Wahab, Mohamed Elagawany, Hoda Daabees, Ahmed S.F.Belal, Ahmed F.EL-Yazbi, Ali H.Eid, Rana Alaaeddine, Rehab R.Hegazy, Rasha M. Allam, [Maged W.Helmy](#), Bahaa Elgendy, Andrea Angeli, Soad A.El-Hawash, Claudiu T. Supuran. **Expanding the anticancer potential of 1,2,3-triazoles via simultaneously targeting Cyclooxygenase-2, 15-lipoxygenase and tumor-associated carbonic anhydrases**. European Journal of Medicinal Chemistry. Volume 200, 15 August 2020, 112439
57. El-Tedawy DM, Abd-Alhaseeb MM, Helmy MW, Ghoneim AI. **Systemic bee venom exerts anti-arthritic and anti-inflammatory properties in a rat model of arthritis**. Biomed Rep. 2020;13(4):20. doi:10.3892/br.2020.1327
58. Mona A. Abdelmoneem, Mahmoud M. Abd Elwakil, Sherine N. Khattab, [Maged W. Helmy](#), Adnan A. Bekhit, Mohammad A. Abdulkader, Amira Zaky, Mohamed Teleb, Kadria A. Elkhodairy, Fernando Albericio, Ahmed O. Elzoghby, **Lactoferrin-Dual Drug Nanoconjugate: Synergistic Anti-Tumor Efficacy of Docetaxel and the NF- $\kappa$ B inhibitor Celastrol**. Materials Science and Engineering: C. August 2020, 111422. doi.org/10.1016/j.msec.2020.111422.
59. Kholod A. Elhasany, Sherine N. Khattab, Adnan A. Bekhit, Doaa M. Ragab, Mohammad A. Abdulkader, Amira Zaky, [Maged W. Helmy](#), Hayam M.A. Ashour, Mohamed Teleb, Nesreen S. Haiba, Ahmed O. Elzoghby. **Combination of magnetic targeting with synergistic inhibition of NF- $\kappa$ B and glutathione via micellar drug nanomedicine enhances its anti-tumor efficacy**. European Journal of Pharmaceutics and Biopharmaceutics, 2020, <https://doi.org/10.1016/j.ejpb.2020.08.004>
60. Nermin A. Khamise, Dalia I. Tayel, Maged W. Helmy, Samar Aborhyem. **Effect of Aspartame and Sucralose Artificial Sweeteners on Weight and Lipid Profile of Male Albino Rats**. Journal of High Institute of Public Health, 2020; 50(2): 87-100. DOI: 10.21608/JHIPH.2020.108281
61. Nasser, F., Moussa, N., [Helmy, M.W.](#) Haroun M.. **Dual targeting of Notch and Wnt/ $\beta$ -catenin pathways: Potential approach in triple-negative breast cancer treatment**. Naunyn-Schmiedeberg's Archives of Pharmacology (2021) 394 (3), 481-490
62. NA El-Sheridy, RM El-Moslemany, AA Ramadan, [MW Helmy](#), LK El-Khordagui. **Enhancing the in vitro and in vivo activity of itraconazole against breast cancer using miltefosine-modified lipid nanocapsules**. Drug Delivery (2021) 28 (1), 906-919
63. M Zewail, N Nafee, [MW Helmy](#), N Boraie. **Synergistic and receptor-mediated targeting of arthritic joints via intra-articular injectable smart hydrogels containing leflunomide-loaded lipid nanocarriers**. Drug Delivery and Translational Research (2021) 11 (6), 2496-2519
64. Passent ME Gaafar, Noha S El-Salamouni, Ragwa M Farid, Heba A Hazzah, [Maged W Helmy](#), Ossama Y Abdallah. **Pegylated liquisomes: A novel combined passive targeting nanoplatform of L-carnosine for breast cancer**. International Journal of Pharmaceutics (2021) 602, 120666



65. DA Freekh, [MW Helmy](#), M Said, NM El-Khodary, *The effect of direct acting antiviral agents on vascular endothelial function in Egyptian patients with chronic hepatitis C virus infection*. Saudi Pharmaceutical Journal(2021) 29 (10), 1120-1128
66. YA Hassan, [MW Helmy](#), AI Ghoneim. *Combinatorial antitumor effects of amino acids and epigenetic modulations in hepatocellular carcinoma cell lines*. Naunyn-Schmiedeberg's Archives of Pharmacology (2021) 394 (11), 2245-2257
67. SM El-Hanboshy, [MW Helmy](#), MM Abd-Alhaseeb. *Catalpol synergistically potentiates the anti-tumour effects of regorafenib against hepatocellular carcinoma via dual inhibition of PI3K/Akt/mTOR/NF- $\kappa$ B and VEGF/VEGFR2*. Molecular Biology Reports (2021) 48 (11), 7233-7242
68. MM Salahuddin, GA Omran, [MW Helmy](#), ME Houssen. *Effect of regorafenib on P2X7 receptor expression and different oncogenic signaling pathways in a human breast cancer cell line: a potential of new insight of the antitumor effects of Regorafenib*. Current Issues in Molecular Biology(2021) 43 (3), 2199-2209
69. AM Youssef, HA Elghoneimy, [MW Helmy](#), AM Abdelazeem, NM El-Khodary *Effect of amlodipine versus bisoprolol in hypertensive patients on maintenance hemodialysis: A randomized controlled trial*. Medicine (2021) 100 (51)
70. NA El-Sheridy, RM El-Moslemany, AA Ramadan, [MW Helmy](#), LK El-Khordagui. *Itraconazole for Topical Treatment of Skin Carcinogenesis: Efficacy Enhancement by Lipid Nanocapsule Formulations*. Journal of Biomedical Nanotechnology(2022) 18 (1), 97-111
71. K Baraka, R Abozahra, [MW Helmy](#), NSED El Meniawy, SM Abdelhamid. *Investigation of the protective and therapeutic effects of Lactobacillus casei and Saccharomyces cerevisiae in a breast cancer mouse model*. AIMS Microbiology(2022) 8 (2), 193-207
72. RH Werida, S Abou-Madawy, M Abdelsalam, [MW Helmy](#). *Omega 3 fatty acids effect on the vascular calcification biomarkers fetuin A and osteoprotegerin in hemodialysis patients*. Clinical and Experimental Medicine (2022) 22 (2), 301-310
73. YH Habiba, GA Omran, [MW Helmy](#), ME Houssen. *Antitumor effects of rhamnazin on sorafenib-treated human hepatocellular carcinoma cell lines via modulation of VEGF signaling and PI3K/NF- $\kappa$ B p38/caspase-3 axes cross talk*. Life Sciences(2022) 297, 120443
74. NA El-Bassiouny, [MW Helmy](#), MAE Hassan, GA Khedr. *The Cardioprotective Effect of Vitamin D in Breast Cancer Patients Receiving Adjuvant Doxorubicin Based Chemotherapy*. Clinical Breast Cancer(2022) 22 (4), 359-366
75. M Youssef, N Moussa, [MW Helmy](#), M Haroun. *Unraveling the therapeutic potential of GANT61/Dactolisib combination as a novel prostate cancer modality*. Medical Oncology(2022) 39 (10), 1-7
76. AHM El-Kishky, N Moussa, [MW Helmy](#), M Haroun. *GANT61/BI-847325 combination: a new hope in lung cancer treatment*. Medical Oncology(2022) 39 (10), 1-11
77. A Salahuddin, H Ghanem, GA Omran, [MW Helmy](#). *Epigenetic restoration and activation of ER $\beta$ : an inspiring approach for treatment of triple-negative breast cancer*. Medical Oncology (2022) 39 (10), 1-11



78. Saleh, N., Mahmoud, H.E., Eltahir, H. *et al.* Prodigiosin-Functionalized Probiotic Ghosts as a Bioinspired Combination Against Colorectal Cancer Cells. *Probiotics & Antimicro. Prot.* **15**, 1271–1286 (2023). <https://doi.org/10.1007/s12602-022-09980-y>
79. Nourhan A Elzayat, Haidy Abbas, Maged W Helmy, Doaa A Habib. Phyto-Therapeutic and Nanomedicinal Approaches: A New Hope for Management of Alzheimer's Disease. *International Journal of Pharmaceutics*. 2022 Nov 5;627:122213
80. Mohamed E. Mahmoud, Azza A. Attia, Maged Wasfy Helmy, Ibrahim H. Hemdan, Magda E. Abouelanwar, Doxorubicin drug release behavior from amino-silanated graphene oxide nanocarrier. *Diamond and Related Material*. (2023) , Volume 131, 109569
81. Nafea, M., Elharoun, M., Abd-Alhaseeb MM, Helmy, MW. Leflunomide abrogates neuroinflammatory changes in a rat model of Alzheimer's disease: the role of TNF- $\alpha$ /NF- $\kappa$ B/IL-1 $\beta$  axis inhibition. *Naunyn-Schmiedeberg's Arch Pharmacol* **396**, 485–498 (2023). <https://doi.org/10.1007/s00210-022-02322-3>
82. Amira E. El-Nahas, Heba M. Elbedaiwy, Inas M. Masoud, Rania G. Aly, Maged W. Helmy, Amal H. El-Kamel. Berberine-loaded zein/hyaluronic acid composite nanoparticles for efficient brain uptake to alleviate neuro-degeneration in the pilocarpine model of epilepsy. *European Journal of Pharmaceutics and Biopharmaceutics*. 2023, Volume 188, 182-200. <https://doi.org/10.1016/j.ejpb.2023.04.008>.
83. Manar A Serageldin , Amira B Kassem , Yasser El-Kerm , Maged W Helmy , Mahmoud M El-Mas , Noha A El-Bassiouny. The Effect of Metformin on Chemotherapy-Induced Toxicities in Non-diabetic Breast Cancer Patients: A Randomised Controlled Study. *Drug Saf* **46**, 587–599 (2023). <https://doi.org/10.1007/s40264-023-01305-4>
84. El-Mas M, Kassem AB, El-Bassiouny NA, Helmy MW, El-Kerm Y, Serageldin MA. Metformin alleviates chemotherapy-induced toxicities in non-diabetic breast cancer patients: a randomized controlled study. *J Pharmacol Exp Ther* June 2023, 385 (S3) 247; DOI: <https://doi.org/10.1124/jpet.122.159900>".
85. Mohamed E. Mahmoud, Mohamed A. Khalifa, Azza A. Attia, Maged Wasfy Helmy, Mahmoud A.B. Al-Sherady, Nesma A. Fekry, **Adsorptive capture of uranium (VI) onto a novel nanocomposite of reduced graphene oxide@titanium dioxide@carboxymethylcellulose**. *Journal of Water Process Engineering*. 2023, Volume 53,103834, <https://doi.org/10.1016/j.jwpe.2023.103834>.
86. Salama, B.M.; [Helmy, M.W.](#); Fouad, H.; Shamaa, M.M.; Houssen, M.E. **The Synergistic Antitumor Effect of Decitabine and Vorinostat Combination on HepG2 Human Hepatocellular Carcinoma Cell Line via Epigenetic Modulation of Autophagy–Apoptosis Molecular Crosstalk**. *Curr. Issues Mol. Biol.* 2023, 45, 5935-5949. <https://doi.org/10.3390/cimb45070375>
87. Christina A. Lamey, Nermine Moussa, [Maged W. Helmy](#), Medhat Haroun, Sally A. Sabra, **Simultaneous encapsulation of dasatinib and celecoxib into caseinate micelles towards improved in vivo anti-breast cancer efficacy with reduced drug toxicity**. *Journal of Drug Delivery Science and Technology*, 2023, 87, ,104807, <https://doi.org/10.1016/j.jddst.2023.104807>.
88. Werida, R., Ramzy, A., Ebrahim, Y., [Helmy, M.](#) **Role of Omega-3 Polyunsaturated Fatty Acid Supplementation in Patients with Type 2 Diabetes Mellitus**. *Journal of Advanced Medical and Pharmaceutical Research*, 2023; ( ): 8-14. doi: 10.21608/jampr.2023.235466.1058
89. YY El Banna, R Abo Ayana, M Nasr, [MW Helmy](#). **PD-1/PD-L1 AXIS INHIBITORS AS PROMISING STRATEGY FOR MANAGEMENT OF HEPATOCELLULAR CARCINOMA: EXPECTATIONS, BOUNDARIES AND PITFALLS**. *Journal of the Medical Research Institute* 44 (2), 1-8



90. Werida, R.H., Ramzy, A., Ebrahim, Y.N. **Helmy, M.W.** Effect of coadministration of omega-3 fatty acids with glimepiride on glycemic control, lipid profile, irisin, and sirtuin-1 in type 2 diabetes mellitus patients: a randomized controlled trial. *BMC Endocr Disord* 23, 259 (2023). <https://doi.org/10.1186/s12902-023-01511-2>
91. Amira E El-Nahas, Heba M Elbedaiwy, Maged W Helmy, Amal H El-Kamel, **Simultaneous Estimation of Berberine and Piperine in a Novel Nanoformulation for Epilepsy Control via HPLC**, Journal of Chromatographic Science, Volume 62, Issue 2, February 2024, Pages 120–126, <https://doi.org/10.1093/chromsci/bmad073>
92. Alian, D.M.E., **Helmy, M.W.**, Haroun, M, Nermin Moussa. **Modulation of autophagy and apoptosis can contribute to the anticancer effect of Abemaciclib/Celecoxib combination in colon cancer cells.** *Med Oncol* 41, 43 (2024). <https://doi.org/10.1007/s12032-023-02288-z>
93. Passent M.E. Gaafar, Ragwa M. Farid, Heba A. Hazzah, HussamElDin Y. AbouKilila, **Maged W. Helmy**, Ossama Y. Abdallah. **Magnetic Lipid-Based hybrid nanosystems: A combined stimuli-responsive nanocarriers for enriched chemotherapeutic potential of L-carnosine in induced breast Ehrlich ascites tumor model.** *International Journal of Pharmaceutics*. Volume 655, (2024)124000, ISSN 0378-5173, <https://doi.org/10.1016/j.ijpharm.2024.124000>.
94. Shaymaa A. Mohamed, **Maged W. Helmy**, Hoda E. Mahmoud, Amira M. Embaby, Medhat Haroun, Sally A. Sabra. **Cinnamaldehyde /naringin co-loaded into lactoferrin/ casienate-coated zein nanoparticles as a gastric resistance oral carrier for mitigating doxorubicin-induced hepatotoxicity.** *Journal of Drug Delivery Science and Technology*, Volume 9., 2024, 105688. <https://doi.org/10.1016/j.jddst.2024.105688>.
95. Marwa Belal, Gihan S. Labib, Doaa A. Ghareeb, **Maged Wasfy Helmy**, Soha M. El-Masry. **Biofriendly resveratrol loaded glycosomal nanovesicles improve wound healing in chronic diabetic foot ulcers: In-vitro & in-vivo efficacy evaluation**, *Journal of Drug Delivery Science and Technology*, Volume 97, 2024, 105805, ISSN 1773-2247, <https://doi.org/10.1016/j.jddst.2024.105805>.
96. Nada M. Salah, Heba M. Elbedaiwy, Maged W. Helmy, Noha S. El-Salamouni, **Topical amlodipine-loaded solid lipid nanoparticles for enhanced burn wound healing: A repurposed approach**, *International Journal of Pharmaceutics*, Volume 662,2024,124484. ISSN 0378-5173, <https://doi.org/10.1016/j.ijpharm.2024.124484>.
97. Ali, E., **Helmy, M.W.**, Radwan, E.H. et al. **Evaluation of the cytotoxic activity of chemically characterized propolis originating from different geographic regions and vitamin D co-supplementation against human ovarian cancer cells.** *J Ovarian Res* 17, 181 (2024). <https://doi.org/10.1186/s13048-024-01500-6>



98. Amira A Zidan, Ahmed YS Gad, Nermine H Zakaria, Hazem M El-Hariri, Noha M Elsharnouby, [Maged W Helmy](#), Maged El-Setouhy. **The use of interleukin-10 (IL-10) and phosphorus levels as predictors of the time to improvement in COVID-19 patients: a prospective study.** Egypt J Bronchol 18, 84 (2024). <https://doi.org/10.1186/s43168-024-00335-5>
99. Fatma M. Abdallah, Asser I. Ghoneim, Mohammad M. Abd-Alhaseeb, Ihab T. Abdel-Raheem, [Maged W. Helmy](#). **Unveiling the antitumor synergy between pazopanib and metformin on lung cancer through suppressing p-Akt/ NF- $\kappa$ B/ STAT3/ PD-L1 signal pathway,** Biomedicine & Pharmacotherapy, Volume 180, 2024, 117468, ISSN 0753-3322, <https://doi.org/10.1016/j.biopha.2024.117468>.
100. [Helmy, M.W.](#), Youssef, M.H., Yamari, I. et al. **Repurposing of sericin combined with dactolisib or vitamin D to combat non-small lung cancer cells through computational and biological investigations.** Sci Rep 14, 27034 (2024). <https://doi.org/10.1038/s41598-024-76947-0>
101. Manar A. Serageldin, Noha A. El-Bassiouny, Yasser El-Kerm, Rania G. Aly, [Maged W. Helmy](#), Mahmoud M. El-Mas, Amira B. Kassem **Randomized controlled study of neoadjuvant metformin with chemotherapy in nondiabetic breast cancer women: The METNEO study.** Br J Clin Pharmacol. 2024; 90(12): 3160-3175. doi:[10.1111/bcp.16193](https://doi.org/10.1111/bcp.16193)
102. [Ghadeer AbouBakr](#) Aly, Sally A. Sabra, Medhat Haroun, [Maged W. Helmy](#) & Nermine Moussa. **Bovine serum albumin nanoparticles encapsulating Dasatinib and Celecoxib for oral cancer: Preparation, characterization, and in-vitro evaluation.** Naunyn-Schmiedeberg's Arch Pharmacol (2025). <https://doi.org/10.1007/s00210-025-03829-1>
103. Kostandy, Samer Osama, Salwa Aburageh Abuissa, Mai Mostafa Helmy, and Maged Wasfy Helmy. **"Context-dependent autophagy in cancer: deciphering cytoprotective vs. cytotoxic roles and therapeutic modulation strategies."** Advances in Medical, Pharmaceutical and Dental Research 5, no. 1 (2025): 38-56.
104. Heneidy, A. M., Mahdy, D. M., Mahmoud, H. E., Ramadan, A. A., Hussein, A., Helmy, M. W., & El-Khordagui, L. (2025). **A prodigiosin/surfactin nanobiotechnological formulation: Development and characterization.** Trends in Pharmacology and Drug Delivery, 1, 39–56. <https://doi.org/10.62184/tpdd.jtpdd110020243>
105. Ahmed Abdelaziz, Mariam Zewail, Haidy Abbas, Maged W. Helmy, Doaa A. Habib, **Exploring roflumilast transferosomes in pluronic-hyaluronic acid hydrogel through comprehensive in-vitro and in-vivo evaluation,** Journal of Drug Delivery Science and Technology, Volume 110, (202), 107081, ISSN 1773-2247, <https://doi.org/10.1016/j.jddst.2025.107081>
106. Tareq Q. Alshargabi, Maged W. Helmy, Saied M. Soliman, Matti Haukka, Assem Barakat, Mohamed Hagar, Mohamed Gaber Marie, Shymaa Abdullah Mohamed, Doaa Hassan Osman, Mohamed G. Bekhit, **Synthesis, X-ray structure, Hirshfeld analysis, molecular docking and anticancer evaluation of 1,2,3-**



**triazole-pyrazolopyrimidine hybrids**, Journal of Molecular Structure, Volume 1345, 2025, 143040, ISSN 0022-2860, <https://doi.org/10.1016/j.molstruc.2025.143040>.

107. Nermeen H. Kamal, Lamia A. Heikal, Basant A. Bakr, Maged W. Helmy, Ossama Y. Abdallah, **HDL and LDL-bioinspired nanocarriers in acellular targeted delivery of Icaritin for cardiac repair post myocardial infarction**, European Journal of Pharmaceutics and Biopharmaceutics, Volume 214, 2025, 114816, ISSN 0939-6411, <https://doi.org/10.1016/j.ejpb.2025.114816>.
108. Mahmoud A. Elgewelly, Soha M. Elmasry, Maged W. Helmy, Haidy Abbas, **Anti-skin cancer efficacy of resveratrol vesicular nanoparticles loaded PVP / poloxamer 407 nanofibers: In vitro and in vivo evaluation**, Journal of Drug Delivery Science and Technology, Volume 114, Part B, 2025, 107585, <https://doi.org/10.1016/j.jddst.2025.107585>.
109. Gaber, D.M., Nafee, N., Helmy, M.W. Osama Y Abdallah. **Inhalable herbal nanotherapeutics targeting lung carcinoma**. Sci Rep 16, 4530 (2026). <https://doi.org/10.1038/s41598-025-18460-6>
110. Zidan, A.A., Gad, A.Y.S., Zakaria, N.H. Helmy, M.W et al. **Effectiveness and safety of cyclosporine A in moderate to severe COVID-19: a randomized, open-label trial**. Sci Rep 16, 6722 (2026). <https://doi.org/10.1038/s41598-026-35292-0>
111. Abrar S. Torky, Riham M. El-Moslemany, Maged W. Helmy, Magda A. El-Massik, **Repurposing the antidepressant sertraline for colorectal cancer: Lactoferrin-functionalized TPGS-enhanced nanostructured lipid carriers in colon-targeted polymeric beads**. Journal of Drug Delivery Science and Technology. Volume 119, 2026,108185, <https://doi.org/10.1016/j.jddst.2026.108185>.
112. El-Hanboshi, S.M., Abdel-Raheem, I.T. & Helmy, M.W. **Repurposing baricitinib and/or rosuvastatin to reinvigorate the anticancer immune response via suppressing PD-1/PD-L1 and CTLA-4 inhibitory immune checkpoints and correlated oncogenic pathways in lung cancer models**. Futur J Pharm Sci 12, 20 (2026). <https://doi.org/10.1186/s43094-026-00937-4>
113. Hassan, M.G., Abdel-Raheem, I.T., Ghoneim, A.I. Helmy, M.W. **Sulfasalazine mitigates cisplatin-induced nephrotoxicity via NF- $\kappa$ B downregulation and upstream modulation of p-AMPK, SIRT1, miRNA-132-3p, and miRNA-375**. Naunyn-Schmiedeberg's Arch Pharmacol (2026). <https://doi.org/10.1007/s00210-026-05009-1>
114. Elgewelly, M. A., Elmasry, S. M., Helmy, M. W., & Abbas, H. (2026). **Potential role of PVP/poloxamer 407 nanofibers loaded with resveratrol nanocrystals in skin cancer therapy**. Journal of Drug Targeting, 1–18. <https://doi.org/10.1080/1061186X.2026.2657595>



115. Gowayed, M.A., Hassan, S.A., Kamel, M.A. Maged W. Helmy & Samar O. El-Ganainy. **Anti-arthritic efficacy of geraniol and methotrexate via miRNA-driven NLRP3 inflammasome suppression in rat adjuvant-induced arthritis.** *Inflammopharmacol* (2026). <https://doi.org/10.1007/s10787-026-02198-2>
116. Emam, H.A.M., Elbedaiwy, H.M., Habib, D.A. , Maged W. Helmy, Eman Badr & Haidy Abbas. **Innovative Berberine-Loaded Nanoparticle Vaginal Pessaries for Effective Vulvovaginitis Therapy.** *J Pharm Innov* 21, 433 (2026). <https://doi.org/10.1007/s12247-026-10624-9>